Cargando…

Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men

BACKGROUND: Gastroprotective agents are recommended for patients receiving low-dose aspirin (LDA) or nonsteroidal anti-inflammatory drugs (NSAIDs). Vonoprazan is a potassium-competitive acid blocker recently approved for the prevention of peptic ulcer recurrence in patients receiving LDA or NSAIDs....

Descripción completa

Detalles Bibliográficos
Autores principales: Sakurai, Yuuichi, Shiino, Madoka, Horii, Sayako, Okamoto, Hiroyuki, Nakamura, Koki, Nishimura, Akira, Sakata, Yukikuni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209422/
https://www.ncbi.nlm.nih.gov/pubmed/27581248
http://dx.doi.org/10.1007/s40261-016-0455-2
_version_ 1782490739251347456
author Sakurai, Yuuichi
Shiino, Madoka
Horii, Sayako
Okamoto, Hiroyuki
Nakamura, Koki
Nishimura, Akira
Sakata, Yukikuni
author_facet Sakurai, Yuuichi
Shiino, Madoka
Horii, Sayako
Okamoto, Hiroyuki
Nakamura, Koki
Nishimura, Akira
Sakata, Yukikuni
author_sort Sakurai, Yuuichi
collection PubMed
description BACKGROUND: Gastroprotective agents are recommended for patients receiving low-dose aspirin (LDA) or nonsteroidal anti-inflammatory drugs (NSAIDs). Vonoprazan is a potassium-competitive acid blocker recently approved for the prevention of peptic ulcer recurrence in patients receiving LDA or NSAIDs. METHODS: This phase 2, open-label, single-center study in healthy Japanese males evaluated drug–drug interactions between vonoprazan 40 mg and LDA (100 mg) or NSAIDs [loxoprofen sodium (60 mg), diclofenac sodium (25 mg), or meloxicam (10 mg)] and vice versa. Subjects were allocated to one of eight cohorts and received their orally administered treatment regimen (to assess the effect of vonoprazan vs. NSAID or LDA, or vice versa) once daily. Endpoints were the pharmacokinetics of plasma concentrations of the study drugs alone and in combination (primary), safety (secondary), and vonoprazan effects on aspirin-mediated inhibition of platelet-aggregation. RESULTS: Of 109 subjects screened, 64 were assigned to one of eight cohorts (n = 8 per cohort) and received treatment, one subject discontinued due to a treatment-emergent adverse event (TEAE), and 63 completed the study. There were few differences in the pharmacokinetics of vonoprazan when administered with LDA or NSAIDs, and few differences in the pharmacokinetics of LDA or NSAIDs when administered with vonoprazan. The differences were small and not clinically meaningful. Inhibition of arachidonic-induced platelet aggregation by LDA was not influenced by vonoprazan. Six patients experienced a TEAE, all were mild and were deemed unrelated to study drugs. One subject withdrew due to infection (tonsillitis). CONCLUSIONS: No clinically meaningful drug–drug interactions were observed and vonoprazan was well tolerated when administered with LDA or NSAIDs. STUDY REGISTRATION: JapicCTI-153100 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40261-016-0455-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5209422
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-52094222017-01-18 Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men Sakurai, Yuuichi Shiino, Madoka Horii, Sayako Okamoto, Hiroyuki Nakamura, Koki Nishimura, Akira Sakata, Yukikuni Clin Drug Investig Original Research Article BACKGROUND: Gastroprotective agents are recommended for patients receiving low-dose aspirin (LDA) or nonsteroidal anti-inflammatory drugs (NSAIDs). Vonoprazan is a potassium-competitive acid blocker recently approved for the prevention of peptic ulcer recurrence in patients receiving LDA or NSAIDs. METHODS: This phase 2, open-label, single-center study in healthy Japanese males evaluated drug–drug interactions between vonoprazan 40 mg and LDA (100 mg) or NSAIDs [loxoprofen sodium (60 mg), diclofenac sodium (25 mg), or meloxicam (10 mg)] and vice versa. Subjects were allocated to one of eight cohorts and received their orally administered treatment regimen (to assess the effect of vonoprazan vs. NSAID or LDA, or vice versa) once daily. Endpoints were the pharmacokinetics of plasma concentrations of the study drugs alone and in combination (primary), safety (secondary), and vonoprazan effects on aspirin-mediated inhibition of platelet-aggregation. RESULTS: Of 109 subjects screened, 64 were assigned to one of eight cohorts (n = 8 per cohort) and received treatment, one subject discontinued due to a treatment-emergent adverse event (TEAE), and 63 completed the study. There were few differences in the pharmacokinetics of vonoprazan when administered with LDA or NSAIDs, and few differences in the pharmacokinetics of LDA or NSAIDs when administered with vonoprazan. The differences were small and not clinically meaningful. Inhibition of arachidonic-induced platelet aggregation by LDA was not influenced by vonoprazan. Six patients experienced a TEAE, all were mild and were deemed unrelated to study drugs. One subject withdrew due to infection (tonsillitis). CONCLUSIONS: No clinically meaningful drug–drug interactions were observed and vonoprazan was well tolerated when administered with LDA or NSAIDs. STUDY REGISTRATION: JapicCTI-153100 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40261-016-0455-2) contains supplementary material, which is available to authorized users. Springer International Publishing 2016-08-31 2017 /pmc/articles/PMC5209422/ /pubmed/27581248 http://dx.doi.org/10.1007/s40261-016-0455-2 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Sakurai, Yuuichi
Shiino, Madoka
Horii, Sayako
Okamoto, Hiroyuki
Nakamura, Koki
Nishimura, Akira
Sakata, Yukikuni
Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men
title Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men
title_full Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men
title_fullStr Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men
title_full_unstemmed Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men
title_short Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men
title_sort pharmacokinetic drug–drug interactions between vonoprazan and low-dose aspirin or nonsteroidal anti-inflammatory drugs: a phase 2, open-label, study in healthy japanese men
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209422/
https://www.ncbi.nlm.nih.gov/pubmed/27581248
http://dx.doi.org/10.1007/s40261-016-0455-2
work_keys_str_mv AT sakuraiyuuichi pharmacokineticdrugdruginteractionsbetweenvonoprazanandlowdoseaspirinornonsteroidalantiinflammatorydrugsaphase2openlabelstudyinhealthyjapanesemen
AT shiinomadoka pharmacokineticdrugdruginteractionsbetweenvonoprazanandlowdoseaspirinornonsteroidalantiinflammatorydrugsaphase2openlabelstudyinhealthyjapanesemen
AT horiisayako pharmacokineticdrugdruginteractionsbetweenvonoprazanandlowdoseaspirinornonsteroidalantiinflammatorydrugsaphase2openlabelstudyinhealthyjapanesemen
AT okamotohiroyuki pharmacokineticdrugdruginteractionsbetweenvonoprazanandlowdoseaspirinornonsteroidalantiinflammatorydrugsaphase2openlabelstudyinhealthyjapanesemen
AT nakamurakoki pharmacokineticdrugdruginteractionsbetweenvonoprazanandlowdoseaspirinornonsteroidalantiinflammatorydrugsaphase2openlabelstudyinhealthyjapanesemen
AT nishimuraakira pharmacokineticdrugdruginteractionsbetweenvonoprazanandlowdoseaspirinornonsteroidalantiinflammatorydrugsaphase2openlabelstudyinhealthyjapanesemen
AT sakatayukikuni pharmacokineticdrugdruginteractionsbetweenvonoprazanandlowdoseaspirinornonsteroidalantiinflammatorydrugsaphase2openlabelstudyinhealthyjapanesemen